Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors

Annals of Oncology

Volumn 16, Issue SUPPL. 4, 2005, Pages

  Morelli, M P ^a   Cascone, T ^a   Troiani, T ^a,b   De Vita, F ^a   Orditura, M ^a   Laus, G ^c   Eckhardt, S G ^b   Pepe, S ^c   Tortora, G ^c   Ciardiello, F ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Combination therapy; Cytotoxic drugs; Epidermal growth factor Receptor inhibitors; Monoclonal antibodies; Small molecule tyrosine kinase inhibitors

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VANDETANIB;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER MODEL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; HUMANS; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PIPERIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS;

EID: 30444445564     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi910     Document Type: Article

References (24)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
2. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-2970.
3. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799.
4. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl Cancer Inst 2003; 95: 851-867.
5. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensivity. J Natl Cancer Inst 1997; 89: 341-343.
6. Prewett MC, Hooper AT, Bassi R et al. Enhanced antitumour activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumour xenografts. Clin Cancer Res 2002; 8: 994-1003.
7. Bruns CJ, Harbison MT, Davis DW et al. Epidermal growth factor receptor antibody blockade with C225 plus gemcitabine results in progression of human pancreatic carcinoma growing orthotopically in nude mice by anti-angiogenetic mechanisms. Clin Cancer Res 2000; 6: 1936-1948.
8. Ciardiello F, Caputo R, Bianco R et al. Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD 1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063.
9. Sirotnak FM, Zakowski MF, Miller VA et al. Efficacy of cytotoxic agent against human tumour xenografts is markedly enhanced by co administration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885-4892.
10. Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9: 1546-1556.
11. Humblet Y. Cetuximab: An IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor expressing tumours. Expert Opin Pharmacother 2004; 5: 1621-1633.
12. Cunningham D, Humblet Y, Siena S et al. A randomized comparison of cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
13. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-784.
14. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-794.
15. Herbst RS, Prager D, Hermann R et al. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol 2004; ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol, 22, No. 14S (July 15 Supplement), 2004: 7011.
16. Gatzemeier U, Pluzanska A, Szczesna A et al. for the TALENT Study Investigators. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22, No 14S (July 15 Supplement), 2004: 7010.
17. Xu J-M, Paradiso A, McLeod HL. Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design? Eur J Can 2004; 40: 1807-1809.
18. Chou TC, Talalay P. Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
19. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In Chau TC, Rideout D (eds): Synergism and antagonism in chemotherapy. New York: Academic Press 1991; 61-102.
20. Tortora G, Caputo R, Pomatico G et al. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin Cancer Res 1999; 5: 875-881.
21. Melisi D, Troiani T, Damiano V et al. Therapeutic integration of signal tranduction targeting agents and conventional anti-cancer treatments. Endocrine Related Cancer 2004; 11: 51-68.
22. Xu JM, Azzariti A, Colucci G et al. Characterization of sequence-dependent synergy between ZD 1839 and oxaliplatin. Biochem Pharmacol 2003; 66: 547-559.
23. Xu JM, Azzariti A, Colucci G et al. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol 2003; 52: 442-448.
24. Azzariti A, Xu J-M, Porcelli L, Paradiso A. Schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with gefitinib (Iressa, ZD1839). Biochem Pharmacol 2004; 68: 135-144.